Comparative Study of Multiple Sclerosis Therapy by Interferon-? and Methylprednisolone of Iraqi Patients via Adenosine Deaminase Activity

A total of 60 patients with multiple sclerosis of both gender (age range 25-60 years) treated with Interferon- and Methylprednisolone in addition to 60 individual divided into two groups 30 as untreated (early onset) patients, all of them were under remission state and 30 individual considered as control were studied to investigate specific activity of adenosine deaminase in serum samples. The results administrated a significantly decreasing of specific activity of adenosine deaminase in all groups which were 139.9411.71, 146.9115.52 and 160.2616.87 U/mg protein respectively as compared with control 195.8816.61 U/mg protein. The study aimed to revelation which of drugs (Interferon- or Methylprednisolone) has a stronger effect in patient treatment as well as adenosine deaminase could suggest to be a biomarker for early detection of Multiple Sclerosis patients and Methylprednisolone consideration a therapeutic drug better than Interferon-.